Helping patients find the Follicular Lymphoma
resources they deserve
How do we help patients?
Massive Bio offers an independent cancer treatment analysis as well as free clinical trial matching for lymphoma cancer patients. Our patient advocates work closely with patients to gather information on their current medical status, and then will provide a list of options from available cancer clinical trials close to your home.
We can also provide a comprehensive case analysis through our Virtual Tumor Board from cancer specialists. The Virtual Tumor Board (VTB) is comprised of highly specialized oncologists from nationally-recognized Cancer Centers of Excellence. In just 7-10 days after receiving your medical records, we can get you a treatment plan without having to travel far distances and use your valuable time.
There are approximately 1,442 Lymphoma clinical trials and 158 trials specific to Follicular Lymphoma that are recruiting patients in the United States right now. With such an extensive list, many of them could be beneficial for you. Our team of patient advocates, who are oncology nurses, and our artificial intelligence based clinical trial matching system will find the best option for you.
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)
Assess the Anti-Tumor Activity and Safety of REGN1979 in Patients With Relapsed or Refractory Follicular Lymphoma
Study of ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies
With just a few clicks, you can see your clinical trial matches now. Click here to use our advanced clinical trial match tool.
Follicular Lymphoma Facts
The five-year survival rate for lymphoma patients is 72%. Lymphoma is the 7th most common cancer type. Lymphoma is more common in men than it is in females. The average age for lymphoma patients is 67 and the average age of death is 76. Follicular Lymphoma is the most common type of indolent lymphoma, meaning that it’s growth is slow moving. In some cases, Follicular Lymphoma can go away without treatment. Patients are monitored to see how the disease progresses. Sometimes Follicular Lymphoma can progress into more aggressive subtypes like diffuse large B-cell Lymphoma.
Lymphoma occurs when white blood cells that fight infection (lymphocytes) grow out of control from genetic changes. A history of immune system problems can also be a risk factor for Lymphoma. For Hodgkin's Lymphoma, most cases are diagnosed in early adulthood, while non-hodgkin's lymphoma patients are typically older than 60. There are several infections that can lead to Lymphoma including HIV, Epstein-Barr virus (EBV), and HCV.
Standard treatment methods for Lymphoma include:
Bone marrow transplant
To screen for Lymphoma, doctors will often check for swollen lymph nodes on a patient’s body. Specifically, in the neck, armpits, and groin. Doctors often recommend a biopsy on a lymph node to see what types of cells are present. Also, bone marrow from the hip can be taken to look at any lymphoma cells that are present. To look for lymphoma cells in other parts of the body, imaging tests can be done. These tests include an MRI, CT scan, or a PET (Positron Emission Tomography scan.
The amount of lymphoma patients has actually increased slightly since 1975 from 18.5 people per 100,000 to 19 people per 100,000 in 2016. Although the number of cases have slightly increased, the number of deaths have dropped considerably from 8 in 1975 to 5.4 deaths per 100,000 people in 2016.
Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Indolent non-Hodgkin Lymphoma:
Marginal Zone Lymphoma
Primary Cutaneous Anaplastic Large Cell Lymphoma
Aggressive Non-Hodgkin Lymphoma types:
Diffuse large B-cell Lymphoma
Anaplastic Large Cell Lymphoma
Extranodal NK-/T-cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Peripheral T-cell Lymphoma
Intravascular Large B-cell Lymphoma
Adult T-cell Leukemia/Lymphoma
Mantle Cell Lymphoma
Our team of patient advocates can help guide you to treatment options you might not have been previously aware of. Although you might be new to cancer, we certainly are not. Navigating cancer patients through the tricky path of finding the best treatment is our goal. No two cancer patients are alike, which is why we find treatment for all of our patients based on their specific genomics, location, stage of cancer, and nearly 100 more data points.